US business under pressure? Margins in focus !

Lupin is scheduled to announce its Q2 FY27 results today, November 3, after market hours. What the market is tracking: Nomura estimates US revenue at approximately $310 million. The brokerage expects EBITDA margin of 23.7%, down around 630 basis points YoY. Domestic formulations growth is expected to remain in the mid-teens. These are brokerage estimates, not reported Q2 results. Why this matters: Lupin's US business faces increased competition in key products, making revenue sustainability and margins important factors this quarter. What to monitor next: US revenue and generic competition EBITDA margin movement India formulations growth New product launches and approvals Management commentary on FY27 guidance My analytical view: Domestic growth remains an important support, but the US business and margin trajectory will determine how the market evaluates this quarter. The earnings call will be important for understanding the outlook. Disclosure: State your actual holding or interest, if any, before publishing. SEBI RA Disclaimer: Umang Rajesh Bhutada is a SEBI-registered Research Analyst (INH000023001). This content is for educational and informational purposes only and is not investment advice. Securities investments are subject to market risks. Please consult a qualified financial professional before making investment decisions.